Small/Middle tier cities and County Lung Cancer Quality Improvement Project (QIP) study

Trial Identifier: D5161L00048
Sponsor: AstraZeneca
Start Date: November 2024
Primary Completion Date: November 2027
Study Completion Date: November 2027
Condition: Lung Cancer; Cancer - Other; Respiratory Syncytial Virus Immunisation

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
China Anning, China
China Anqing, China
China Changzhi, China
China Daqing, China
China Dazhou, China
China Dazhu, China
China Dingzhou, China
China Ganzhou, China
China Guang'an, China
China Guangzhou, China
China Hanzhong, China
China Hebi, China
China Hengyang, China
China Huaibei, China
China Jining, China
China Jinzhou, China
China Liyang, China
China Lu'an, China
China Meihekou, China
China Nanchong, China
China Nanyang, China
China Ningde, China
China Ningxiang, China
China Panjin, China
China Pingxiang, China
China Quanzhou, China
China Shengzhou, China
China Suzhou, China
China Taizhou, China
China Tancheng, China
China Tongling, China
China Wafangdian, China
China Weifang, China
China Wuzhou, China
China Xiangtan, China
China Xianning, China
China Xiantao, China
China Xixian, China
China Xuzhou, China
China Yangjiang, China
China Yangzhou, China
China Yibin, China
China Yichun, China
China Yingkou, China
China Zhangjiakou, China
China Zhuji, China